Keyphrases
COVID-19
63%
Influenza
55%
Virus
47%
Influenza Virus
41%
United Kingdom
36%
Vaccine Effectiveness
25%
Vaccination
24%
H3N2
24%
Hemagglutination Inhibition
21%
Influenza-like Illness
21%
Adjuvanted
21%
Respiratory Syncytial Virus
20%
Neuraminidase Inhibitors
19%
Influenza Vaccine
19%
Primary Care
19%
Influenza A
18%
Confidence Interval
17%
A(H1N1)pdm09
16%
H1N1
16%
World Health Organization
15%
Europe
15%
Hemagglutinin
14%
Influenza Season
14%
Antibody Response
14%
Neuraminidase
14%
Immunogenicity
14%
SARS-CoV-2 Infection
12%
H3N2 Virus
12%
Quantitative PCR
12%
Influenza B
11%
Seasonal Influenza Vaccine
11%
Human Influenza
11%
Neutralizing Antibodies
11%
Laboratory-confirmed Influenza
11%
Oseltamivir
11%
Titre
11%
Severe Acute Respiratory Syndrome
10%
Live Attenuated Influenza Vaccine
10%
Influenza Vaccination
9%
Avian Influenza
9%
Influenza Vaccine Effectiveness
9%
Vaccine Adjuvant
9%
Care Homes
9%
H5N1
8%
Prospective Cohort Study
8%
Influenza A(H3N2)
8%
Ferret
8%
Receptor-binding Domain
7%
Influenza B Virus
7%
Infection Rate
7%
Influenza Surveillance
7%
Age Groups
7%
Reinfection
7%
COVID-19 Pandemic
7%
SARS-CoV-2 Variants
7%
Sentinel
7%
Unvaccinated
7%
Vaccine Strain
7%
Wales
6%
Revaccination
6%
Healthcare Workers
6%
Patients with COVID-19
6%
Microneutralization
6%
Seroprevalence
6%
H5N1 Vaccine
6%
Spike Protein
6%
Surveillance Data
6%
Two-dose
6%
Hospitalized Patients
6%
Illness
6%
MF59
5%
Seroconversion
5%
Virion
5%
Oseltamivir-resistant
5%
Immunization
5%
Influenza A (H1N1) 2009
5%
Siren
5%
Epidemiology
5%
COVID-19 Vaccine
5%
Variants of Concern
5%
Surveillance System
5%
Zanamivir
5%
Hospital Admission
5%
Seroconversion Rate
5%
Influenza Activity
5%
Primary Infection
5%
Whole Genome Sequencing
5%
Influenza A(H1N1)pdm09 Virus
5%
Pandemic Influenza Virus
5%
Resistant Virus
5%
T Cell Response
5%
ISARIC
5%
Blood Donors
5%
Immunology and Microbiology
Influenza
100%
Virus
64%
Influenza A Virus (H1N1)
41%
Severe Acute Respiratory Syndrome Coronavirus 2
37%
Influenza Virus
35%
Influenza Vaccine
30%
Influenza A Virus (H3N2)
23%
COVID-19
17%
Influenzavirus A
17%
Neuraminidase Inhibitor
17%
Hemagglutination Inhibition
17%
Antibody Response
16%
Influenza A Virus (H5N1)
15%
Hemagglutinin
13%
Immunogenicity
13%
Spike
12%
Aves
11%
Viral Disease
10%
Human Respiratory Syncytial Virus
10%
T Cell
9%
Receptor Binding
9%
Coronavirinae
8%
Antibody Titer
8%
Mustela Putorius Furo
8%
Cladistics
8%
Neutralizing Antibody
8%
Severe Acute Respiratory Syndrome
7%
Immune Response
6%
MF59
6%
Seroprevalence
6%
Viral Load
6%
Seroconversion
6%
Influenza B Virus
5%
Wild Type
5%
Titer
5%
Humoral Immunity
5%
Respiratory Virus
5%
IC50
5%
Lineages
5%
Medicine and Dentistry
COVID-19
50%
Severe Acute Respiratory Syndrome Coronavirus 2
49%
Infection
39%
Influenza Vaccine
29%
Virus
26%
Primary Health Care
21%
Influenza A Virus (H3N2)
17%
Influenza Virus
14%
Influenza A Virus (H1N1)
13%
Public Health
12%
Diseases
11%
Human Respiratory Syncytial Virus
10%
Prospective Cohort Study
9%
Hemagglutination Inhibition
9%
Influenza B
9%
Cohort Analysis
9%
Sialidase Inhibitor
8%
Influenza Vaccination
8%
Observational Study
7%
Influenza A (H1N1)
6%
Immunogenicity
6%
Coronavirinae
6%
Influenza A (H3N2)
6%
Severe Acute Respiratory Syndrome
5%
Influenza A Virus
5%
Influenza A
5%
General Practitioner
5%
COVID-19 Vaccine
5%
Reinfection
5%
Respiratory Disease
5%